Beractant
| Clinical data | |
|---|---|
| Trade names | Survanta, Alveofact |
| Routes of administration | Endotracheal |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
108778-82-1  |
| ChemSpider | none |
| UNII |
S866O45PIG  |
| ChEMBL |
CHEMBL1201624 |
| (what is this?) (verify) | |
Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.[2]
References
- ↑ Moya, F. R.; Gadzinowski, J.; Bancalari, E.; Salinas, V.; Kopelman, B.; Bancalari, A.; Kornacka, M. K.; Merritt, T. A.; Segal, R.; Schaber, C. J.; Tsai, H.; Massaro, J.; d'Agostino, R. (1 April 2005). "A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants". PEDIATRICS. 115 (4): 1018–1029. doi:10.1542/peds.2004-2183.
- ↑ Lotze, Andrea; Mitchell, Brian R.; Bulas, Dorothy I.; Zola, Elizabeth M.; Shalwitz, Robert A.; Gunkel, J.Harry (January 1998). "Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure". The Journal of Pediatrics. 132 (1): 40–47. doi:10.1016/S0022-3476(98)70482-2.
This article is issued from Wikipedia - version of the 9/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.